Associate Director
Alexion
Associate Director
Alexion
Global biopharmaceuticals focusing on rare diseases
This role is based in Barcelona, with an on-site commitment of three days a week. Fluency in English is required.
Are you ready to architect and scale secure MLOps and LLMOps capabilities that turn cutting-edge AI into measurable impact for patients and the business? Do you want to own the platform vision that empowers teams to deliver production-grade AI quickly, safely and cost-effectively from Barcelona, Spain?
As Associate Director, RDU IT – MLOps, you will report to the AI Director and lead the strategy, architecture, delivery and governance of our enterprise AI platform and accelerators. You will define the paved road for reusable services, set engineering standards, and embed responsible AI so teams across the organization can deploy agentic and generative AI with confidence.
Your leadership will shape future-ready solutions aligned to enterprise architecture, security and regulatory needs. From day one, you will drive outcomes: faster time-to-value for AI products, stronger operational resilience, and year-on-year improvements in unit economics for large-scale model and LLM workloads.
When we put unexpected teams in the same room, we unleash bold thinking with the power to inspire life-changing medicines. In-person working gives us the platform we need to connect, work at pace and challenge perceptions. That's why we work, on average, a minimum of three days per week from the office. But that doesn't mean we're not flexible. We balance the expectation of being in the office while respecting individual flexibility. Join us in our unique and ambitious world.
Why AstraZeneca: Here you will join a mission-led community that pairs deep compassion for people living with serious and rare conditions with the scale and science to act. We bring diverse experts together to spark bold ideas, apply advanced cloud and AI technologies, and turn them into solutions that matter for patients and the teams who serve them. You will be supported by leaders who value kindness alongside ambition, encouraged to experiment responsibly, and trusted to build the platforms that others rely on to deliver therapies faster and more reliably.
Call to Action: If you are ready to build the AI platform that powers life-changing impact from Barcelona, take the lead and submit your application to shape what comes next!
Date Posted
04-nov-2026Closing Date
17-nov-2026Alexion is proud to be an Equal Employment Opportunity and Affirmative Action employer. We are committed to fostering a culture of belonging where every single person can belong because of their uniqueness. The Company will not make decisions about employment, training, compensation, promotion, and other terms and conditions of employment based on race, color, religion, creed or lack thereof, sex, sexual orientation, age, ancestry, national origin, ethnicity, citizenship status, marital status, pregnancy, (including childbirth, breastfeeding, or related medical conditions), parental status (including adoption or surrogacy), military status, protected veteran status, disability, medical condition, gender identity or expression, genetic information, mental illness or other characteristics protected by law. Alexion provides reasonable accommodations to meet the needs of candidates and employees. To begin an interactive dialogue with Alexion regarding an accommodation, please contact [email protected]. Alexion participates in E-Verify.
Alexion, now the rare disease group within AstraZeneca, develops and sells therapies for rare and ultra-rare diseases by targeting the complement immune system. Its drugs, such as Soliris and Ultomiris, inhibit the C5 component to slow or stop disease processes, while Strensiq and Kanuma address specific metabolic disorders. It differentiates itself through a deep focus on complement biology, pursuing first- or best-in-class therapies, and using a strategy that blends internal R&D with acquisitions to expand its pipeline. Its goal is to improve outcomes for patients with rare diseases and bring these therapies to a broader international market using AstraZeneca’s scale and capabilities.
Explore more opportunities at Alexion